Creation of de novo cryptic splicing for ALS and FTD precision medicine

利用从头隐蔽剪接技术进行ALS和FTD精准医疗

阅读:2
作者:Oscar G Wilkins ,Max Z Y J Chien # ,Josette J Wlaschin # ,Simone Barattucci ,Peter Harley ,Francesca Mattedi ,Puja R Mehta ,Maria Pisliakova ,Eugeni Ryadnov ,Matthew J Keuss ,David Thompson ,Holly Digby ,Lea Knez ,Rebecca L Simkin ,Juan Antinao Diaz ,Matteo Zanovello ,Anna-Leigh Brown ,Annalucia Darbey ,Rajvinder Karda ,Elizabeth M C Fisher ,Thomas J Cunningham ,Claire E Le Pichon ,Jernej Ule ,Pietro Fratta

Abstract

Loss of function of the RNA-binding protein TDP-43 (TDP-LOF) is a hallmark of amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Here we describe TDP-REG, which exploits the specificity of cryptic splicing induced by TDP-LOF to drive protein expression when and where the disease process occurs. The SpliceNouveau algorithm combines deep learning with rational design to generate customizable cryptic splicing events within protein-coding sequences. We demonstrate that expression of TDP-REG reporters is tightly coupled to TDP-LOF in vitro and in vivo. TDP-REG enables genomic prime editing to ablate the UNC13A cryptic donor splice site specifically upon TDP-LOF. Finally, we design TDP-REG vectors encoding a TDP-43/Raver1 fusion protein that rescues key pathological cryptic splicing events, paving the way for the development of precision therapies for TDP43-related disorders.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。